Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

Clinical trial NCT05544552 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05544552
Sponsor: Tyra Biosciences, Inc
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Locally Advanced Urothelial Carcinoma Metastatic Urothelial Carcinoma Solid Tumor Urothelial Carcinoma Solid Tumor, Adult Bladder Cancer Non-muscle-invasive Bladder Cancer FGFR3 Gene Mutation FGFR3 Gene Alteration Advanced Solid Tumor Advanced Urothelial Carcinoma Urinary Tract Cancer

Start date: 2022-11-22
Primary completion: 2026-11-01
Enrollment: 310

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.